Study #2023-0655
An open label, multicenter, phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor m1774 in combination with emiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-pd-(l)1 and platinum-based therapies
MD Anderson Study Status
Not Accepting
Treatment Agent
M1774, Cemiplimab
Description
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Small Cell Lung Cancer
Study phase:
Physician name:
Natalie Vokes
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-479-2433
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.